The dog is an important companion animal and also purpose-bred for research studies. Coagulopathies in dogs are common, although the availability of blood products for therapy is inconsistent throughout the profession. A pro-coagulant therapeutic that is readily available and easily stored would be useful for the treatment of coagulopathies. Tricarbonyldichlororuthenium (II) dimer [Carbon monoxide-releasing molecule-2 (CORM-2)] acts as a prothrombotic agent in plasma by increasing the velocity of clot formation and clot strength, and by decreasing the clot's vulnerability to fibrinolysis. We sought to test CORM-2's effect on coagulation and fibrinolysis in vitro in canine plasma using thromboelastography. Measures of the rate of clot formation and clot strength in plasma without CORM-2 were highly correlated with fibrinogen concentration. We found that CORM-2 significantly enhanced the rate of clot formation and clot strength and significantly reduced the rate of fibrinolysis and the clot lysis time. The per cent change in rate of clot formation and clot strength was not significantly correlated with fibrinogen concentration, indicating that CORM-2's pro-coagulant effect is not dependent on fibrinogen concentration. This study corroborates studies in other species that show that CORM-2 is pro-coagulant in plasma, and lays the groundwork for developing CORM-2 as a therapeutic agent for canine coagulopathies. Future studies will evaluate the effect of CORM-2 on whole blood both in vitro and in vivo.
Coagulopathies in dogs include von Willebrand's disease, congenital factor deficiencies, hypofibrinogenaemia, acute traumatic coagulopathy, venom-mediated coagulopathy and disseminated intravascular coagulation [1] [2] [3] [4] [5] [6] . Additionally, dogs are used as models for the study of inherited and acquired bleeding disorders [7] [8] [9] [10] . Blood products (whole blood, packed erythrocytes, fresh frozen plasma) are often used to treat these conditions, but outside of private referral or veterinary teaching hospitals, these products can be expensive and difficult to obtain for general veterinary practitioners [11, 12] . Additionally, the use of blood products carries inherent risk of alloimmunization and potential transfusion reactions [13] . A therapeutic agent that enhances coagulation and diminishes fibrinolysis would be helpful for coagulopathic dogs for whom blood products are unavailable or not the ideal therapy.
Carbon monoxide-releasing molecules (CORMs), studied as therapeutics since 2006, liberate CO once they are solubilized [14, 15] . CO via releasing molecules has been found to mitigate inflammation and other cell-damaging events, although it has also been shown to cause erythrocyte damage [16] [17] [18] . Carbon monoxide-releasing molecule-2 (CORM-2) or tricarbonyldichlororuthenium (II) dimer acts as a prothrombotic agent in plasma by increasing the velocity of clot formation and clot strength, and by decreasing the clot's vulnerability to fibrinolysis [19] [20] [21] [22] . However, it is also antithrombotic in whole blood because it inhibits platelet function [23, 24] . Both of these effects are due to the action of CO, which alters the fibrinogen molecule and acts as a signalling agent to platelet receptors [20, [24] [25] [26] . Work completed in human plasma has elucidated that CO released via solubilized CORM-2 interacts with a haem group bound to fibrinogen, causing a conformational change to fibrin ultrastructure to that of thin fibre versus the more normal thick fibre formation [25, 26] . As a result, clots have more tightly packed fibrin strands, creating stronger clots that are more resistant to fibrinolysis. This is in contrast to thick fibre fibrin clots which contain turbid, loosely woven fibrin that is weaker in structure and more readily lysed during fibrinolysis [27] .
We used thromboelastography (TEG) to test whether CORM-2 augments coagulation and diminishes fibrinolysis in canine plasma in vitro by collecting standard and viscoelastic measurements of clots as they form and lyse. The purpose of our work in canine plasma was threefold: (i) to determine whether CORM-2 augments coagulation; (ii) to identify whether fibrinogen concentration influences coagulation parameters and response to CORM-2 exposure; and (iii) to determine whether CORM-2 slows fibrinolysis. We hypothesized that CO delivered to plasma via CORM-2 would enhance coagulation and slow fibrinolysis and that clot strength, coagulation velocity and response to CORM-2 exposure would directly correlate with fibrinogen concentration.
Materials and Methods
Plasma samples. Thirty-four clinically normal mixed-breed and purebred dogs owned by students and staff of the Colorado State Author for correspondence: Christine Olver, Colorado State University, 1644 Campus Delivery, Fort Collins, CO 80523, USA (e-mail colver@colostate.edu).
University Veterinary Medical Center were deemed healthy based on physical examination (SY), owner assessment, and/or normal results of a serum diagnostic profile (Cobas), complete blood count (Siemens ADVIA 120) and standard coagulation profile (Stago Compact MAX). Excluding heartworm and flea prophylaxis, the dogs had not received any medications for 6 months preceding the study. Plasma was harvested from whole blood collected from the jugular vein into tubes containing 3.2% sodium citrate (Vacutainer) and centrifuged at 3800 9 g for 20 min., and was frozen at À80°C until tested. Thromboelastography. Prior to analysis, frozen samples were quickly thawed in a 37°C warming block or water bath. Samples were assayed with a computer-controlled thromboelastograph instrument (Model 5000; Haemoscope Corp., Niles, IL, USA). Machine balance and e-tests were verified prior to testing daily. In addition to the standard TEG parameters, R, alpha angle, MA and G, viscoelastic parameters were collected [28] . These include time to maximum rate of thrombus generation (TMRTG), the time interval (min.) observed prior to maximum speed of clot growth, maximum rate of thrombus generation (MRTG), the maximum velocity of clot growth (dynes/ cm 2 /sec.), total thrombus generation (TTG), the total area under the velocity curve during clot growth (dynes/cm 2 ), time to maximum rate of lysis (TMRL) maximum rate of lysis (MRL), the maximum velocity of clot lysis (dynes/cm 2 /sec.), clot growth time (CGT), the time (min.) from clot amplitude of 2 mm until maximum clot strength is achieved, clot lysis time (CLT), the time (min.) from when maximum strength observed to 2 mm amplitude, and clot lifespan (CLS), the sum of CGT and CLT. These values are provided by TEG Analytical Software version 4.2 (Haemoscope Corp., Niles, IL, USA).
Reagents
Coagulation-only assays. Twenty-six dogs were used for the coagulation-only studies. The final concentrations in the TEG cups were plasma (325 lL), TF (10 lL), DMSO (3.6 lL) or CORM-2 (3.6 lL, 10 mM, final concentration 100 lM). The reagents were preincubated at 37°C in microcentrifuge tubes prior to placing in the cup. Lastly, 0.2 M calcium chloride (20 lL) was added. The sample cup was gently raised and lowered five times to mix the sample immediately prior to initiation of assay. Data were collected until maximum amplitude was stable.
Coagulation and fibrinolytic assays. Eight dogs were used for the studies that included fibrinolysis measurements. The final concentration of tPA was determined by titrating the concentration which maximized fibrinolysis without completely abrogating clot formation in plasma from four dogs. Briefly, tPA final concentrations of 100, 200 and 300 U/mL were evaluated in TF-activated citrated plasma from four dogs. A tPA concentration of 100 U/mL did not induce or induced very slow fibrinolysis in all four dogs. A tPA concentration of 200 U/mL induced fibrinolysis reliably without completely eliminating clot formation in all four dogs. A tPA concentration of 300 U/mL completely eliminated clot formation in plasma from three of the four dogs. Therefore, the final tPA concentration of 200 U/mL was chosen for evaluation of fibrinolysis (data not shown). The reagents were added directly to the cup, and volumes were identical to coagulation experiments except that only 315 lL of plasma and 10 lL of tPA were used. Data were collected until clot lysis was completed, or if clot lysis was not occurring, until the assay was terminated.
Statistical analysis. The data are presented as mean AE standard deviation. Using commercial software (Prism version 7.0; GraphPad Software, Inc., San Diego, CA, USA), data were assessed for normality of distribution using the D'Agostino-Pearson omnibus normality test. Analysis of the effects of CORM-2 on coagulation and fibrinolysis parameters was performed with paired t-tests for normally distributed data or a Wilcoxon matched-pairs signed rank test for nonnormally distributed data. Three of eight of the fibrinolysis samples did not lyse with tPA and were given a CLT matching the time that the assay was terminated. Correlation of measured TEG parameters with fibrinogen concentration was performed by calculating the Pearson correlation coefficient for normally distributed data or the Spearman's rank correlation coefficient for non-normally distributed data.
Results

CORM-2 enhances clot strength and rate of clot formation in plasma from normal dogs.
The TEG parameters for control and CORM-2-exposed plasma, as well as the mean per cent change after CORM-2 exposure, are displayed in table 1. Exposure of plasma to CORM-2 increased the mean rate of coagulation, as measured by alpha and MRTG, by 6% and 37%, respectively, and increased clot strength, as measured by MA, G and TTG, by 43.6%, 57.5% and 57%, respectively. Neither R nor TMRTG was significantly altered by the presence of CORM-2. In spite of the statistical significance of the changes, the individual variation in response to CORM-2 was marked. For example, the per cent change in TTG ranged from 16.4% to 105.6%.
Clot strength, rate of clot formation and absolute response to CORM-2 are correlated with fibrinogen concentration. Table 2 shows that all measures of clot strength and two measures of clot velocity (alpha and MRTG) are strongly and significantly correlated with fibrinogen concentration. The data reveal that the absolute change in these parameters after CORM-2 exposure is also highly correlated with fibrinogen concentration. Conversely, the magnitude of the CORM-2 response measured as a percentage of measurements without CORM-2 is not correlated with fibrinogen concentration for any parameter (data not shown).
CORM-2 reduces fibrinolysis in plasma from normal dogs.
To test whether CORM-2 could also enhance overall CLS by reducing the clot's vulnerability to lysis, we measured coagulation and fibrinolysis in plasma from eight additional dogs with and without CORM-2 exposure. Coagulation-only variables are shown in table 3A, and fibrinolysis variables (with tPA included) are shown in table 3B. CORM-2 enhanced plasmatic coagulation as described for the initial group of dogs and attenuated fibrinolysis in all eight dogs. The plasma lysed completely (amplitude <2 mm) in only one CORM-2-exposed sample, and the clots of three of the dogs did not lyse at all. Thus, neither the MRL nor the time to MRL could be measured in these dogs. For the remaining four dogs, complete clot lysis was not reached, but MRL and TMRL values were provided by the instrument. The CLT for all CORM-2-exposed plasma was recorded based on the time of the last measurement taken. Statistical analysis of the five dogs that showed some lysis revealed that MRL was decreased by 82% and the TMRL was prolonged by 80%. The CLT was prolonged by almost fivefold, and the overall CLS was prolonged by 4.8-fold. Data from the plasma from individual dogs are shown in table 4.
Discussion
We have evaluated plasmatic coagulation and fibrinolysis in normal dog plasma both with and without tPA using TEGderived viscoelastic measurements. To our knowledge, this is the first report showing the velocity and strength of plasmatic coagulation and fibrinolysis in individual normal dogs, rather than canine-pooled plasma [29] , and the first report to show the coagulation-enhancing effects of CORM-2 in dogs. Our data demonstrate that clot strength and rate of clot formation were correlated with fibrinogen concentration. We also showed that while the absolute response to CORM-2 was correlated with fibrinogen concentration, the per cent response was not. This shows that CORM-2 has important strengthening effects in low-fibrinogen samples as well as high-fibrinogen samples, which may be important clinically. TEG measurements often only include 'standard', nonparametric measures. The CLS model measures the parametric elastic modulus through clot formation and lysis (when tPA is added) using dynes/cm 2 [28, 30] . TEG software (version 4.2;
Haemoscope, Inc.) calculates these parameters by converting changes in amplitude to changes in G over time, and these be exported as 'velocity curves'. This model offers more sensitivity for detecting changes in rate and strength of clot formation than the conventional nonparametric measurements in mm [28] . We showed that fibrinogen concentration is highly correlated with the rate and strength of clot formation. This has been shown in canine whole blood with variable strength of association, but has not been yet documented in canine plasma [4, 31, 32] . Only one report describes the positive significant correlation of fibrinogen concentration with rate of coagulation [32] . None of these studies evaluated the elastic modulus variables but rather used the standard variables (R, K, a, MA). It is important to understand the role that fibrinogen plays in the rate and strength of clot formation for clinical use, and for future studies. For instance, fibrinogen concentration was positively correlated with the plasma response to CORM-2 in human plasma, although at the smallest and largest concentrations of fibrinogen the effect was minimal [33] . Our data show that dog plasma responds to CORM-2 as a percentage from control that is not related to the fibrinogen concentration, indicating that CORM-2 treatment would be beneficial regardless of the patient's fibrinogen concentration. Thrombin and factor XIII concentrations are also positively correlated with rate and strength of clotting in plasma measured by TEG, and these were not examined in this study [34] . Fibrinogen concentration has a positive correlation with measures of clot strength and rate of clot formation in vitro in whole blood in dogs and pigs, and platelet poor plasma in pigs [32] [33] [34] [35] [36] . Additionally, Table 2 . TEG values for clot strength, rate of clot formation and absolute change after CORM-2 exposure are significantly correlated with fibrinogen concentration. Nielsen et al. [33] showed that the clot strengthening response of plasma to CORM-2 was affected by fibrinogen concentration in mg/dL. However, to our knowledge, no investigators have evaluated the effect of fibrinogen concentration on TEG variables with or without CORM-2 in canine platelet poor plasma. It is important to understand this correlation when testing a potential therapeutic that affects fibrinogen behaviour during coagulation.
CORM-2 enhanced coagulation by increasing both the rate of clot formation and the final clot strength in our normal dog plasma. CORM-2 coagulation-enhancing effects have been seen in all species tested, although there is variability in the degree of response. CORM-2 exposure enhanced the TTG by 25% and 23% in the rabbit and rat, respectively, in horses only by 9.3%, in dogs and pigs (V. Nielsen, data not shown, personal communication) by 57% and 43%, respectively, and in human beings by 54% [22, 26, 37] . In human plasma, CO released from CORM-2 binds to a haem group on the fibrinogen molecule, modifying the same peptide groups on the alpha and gamma chains that are used for polymerization. This has the effect of making fibrinogen a better substrate for thrombin, with a resultant stronger clot, even in factor XIII-deficient plasma. Exposure to CORM-2 decreases thick fibre formation and increases thin fibre formation [25] , a construction that increases clot strength and reduced fibrinolytic vulnerability [27] . Although this exact mechanism has not been tested in the plasma of other species, the end result of CO-enhanced coagulation is the same as it is in human beings.
Using the representative measurement of TTG, dog plasma, with a mean of 108.5 dynes/cm 2 , is hypocoagulable compared with almost all species tested (horse, 313 dcs; pig, 230 dcs; human being, 168 dcs; rabbit, 232 dcs; and rat, 188 dcs) in previous reports [20, 22, 37, 38] . The same is true for the rate of clotting. The mean MRTG was 5.3 dynes/cm 2 /sec., whereas the range of MRTG in the above species was from 7.4 dcs/sec. in the human beings to 13.4 dcs/ R (min.) = time from initiation to 2 mm amplitude; angle (deg) = rate of clot formation; MA (mm) = maximum amplitude; G (dynes/cm 2 ) = total clot strength; MRTG (dynes/cm 2 /sec.) = maximum rate of thrombus generation; TMRTG (min.) = time to MRTG; TTG (dynes/cm 2 ) = total thrombus generation; MRL (dynes/cm 2 /sec.) = maximum rate of lysis; CGT (min.) = clot growth time; CLT (min.) = clot lysis time; CLS (min.) = clot lifespan; CORM-2 = carbon monoxide-releasing molecule-2; tPA = tissue plasminogen activator. *p < 0.05 using paired t-test; **p < 0.05 using Wilcoxon rank sum. MRL (dynes/cm 2 /sec.) = maximum rate of lysis; CGT (min.) = clot growth time; CLT (min.) = clot lysis time; the time (min.); CLS (min.) = clot lifespan; TF = tissue factor at a final dilution of 0.1% v/v. tPA = tissue plasminogen activator at a final concentration of 200 U/mL; CORM-2 = carbon monoxide-releasing molecule-2.
sec. in the horse. Overall, compared with other species tested, the dog is closest to the human beings for rate and strength of the plasma clot, suggesting that the dog may be a good model for human coagulation. Additionally, we have shown that as for all species tested so far, plasma CORM-2 exposure enhances rate of clot formation and clot strength and reduces the clot's vulnerability to lysis. Although a necessary limitation of this study is that we used plasma, not whole blood, to assess the effects of CORM-2 on coagulation and fibrinolysis, these findings lay the groundwork for future studies evaluating the benefits of CORM-2 exposure on enhancing coagulation in pre-clinical studies and in canine clinical coagulopathies.
